AkzoNobel stock trades at EUR 56.52 as margins expand

Published on 09/29/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AkzoNobel stock has a Q2 earnings anchor as adjusted EBITDA reached EUR 398.00 million, up 5.00 percent at comparable scope. The 2026 target stays at or above EUR 1.47 billion.

Farbenfabrik von Akzo Nobel N.V. an einer Amsterdamer Gracht — Fotorealistische Industrieanlage zeigt Chemiebranche von Akzo Nobel N.V. mit ISIN NL0013267909 an Amsterdamer Gracht, Illustration mit AI erstellt.

AkzoNobel stock (ISIN NL0013267909) was trading at EUR 56.52 at Lang & Schwarz on September 29, 2026 at 11:12 a.m. CEST, up 0.11 percent versus the Euronext Amsterdam close of EUR 56.46. The investment case is being shaped by improving margins, a firm 2026 earnings target and regulatory scrutiny of the proposed Axalta combination.

Q2 margin expansion continues

According to the Yahoo Finance transcript dated July 22, 2026, AkzoNobel reported Q2 adjusted EBITDA of EUR 398.00 million, up 5.00 percent at comparable scope. Adjusted EBITDA margin reached 15.40 percent, an increase of 0.40 percentage points from the prior year.

The operating detail was mixed but constructive. Organic sales increased 2.00 percent year over year, pricing rose 3.00 percent and volumes were stable, while total revenue declined 1.00 percent after the India business disposal and currency effects. The figures show how pricing and cost control are currently doing more work than volume growth.

EUR 1.47 billion target remains

Management kept its 2026 adjusted EBITDA target at or above EUR 1.47 billion, according to the same July 22 earnings call. The target includes EUR 90.00 million of net savings from the Industrial program, making execution of the cost agenda a central test for the second half.

AkzoNobel also disclosed EUR 108.00 million of Q2 free cash flow and net leverage of 2.20 times. That combination gives the company financial flexibility while merger preparations continue, but it also leaves investors watching the balance between integration spending, raw-material inflation and cash generation.

Axalta review adds a risk factor

Reuters reported on September 17, 2026, that Britain's competition watchdog opened a probe into AkzoNobel's USD 25.00 billion merger with Axalta. The review is a concrete counter-factor because the proposed transaction is also a source of the synergy potential embedded in the company's longer-term strategy.

The next scheduled earnings checkpoint is October 21, 2026, according to Investing.com. Its quoted analyst consensus showed an average 12-month price target of EUR 65.25 as of September 27, 2026, compared with the EUR 56.52 Lang & Schwarz price used here.

Stock remains below yearly high

AkzoNobel was trading at EUR 56.52 at Lang & Schwarz on September 29, 2026 at 11:12 a.m. CEST, up 0.11 percent versus the Euronext Amsterdam close of EUR 56.46. The Euronext Amsterdam 52-week range was EUR 46.18 to EUR 67.64 on September 29, 2026, while market capitalization stood at EUR 9.7 billion.